These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 30085269)

  • 21. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
    Agrawal S; Arora S; Amiri-Kordestani L; de Claro RA; Fashoyin-Aje L; Gormley N; Kim T; Lemery S; Mehta GU; Scott EC; Singh H; Tang S; Theoret MR; Pazdur R; Kluetz PG; Beaver JA
    JAMA Oncol; 2023 Feb; 9(2):266-272. PubMed ID: 36580315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
    de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
    Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
    Liu ITT; Kesselheim AS; Cliff ERS
    JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. US FDA oncology drug approvals in 2014.
    Wolford JE; Tewari KS
    Future Oncol; 2015; 11(13):1931-45. PubMed ID: 26039742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
    Ribeiro TB; Buss L; Wayant C; Nobre MRC
    PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
    Zettler ME
    Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US Food and Drug Administration regulatory updates in neuro-oncology.
    Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
    J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meaningful endpoints for therapies approved for hematologic malignancies.
    Smith BD; DeZern AE; Bastian AW; Durie BGM
    Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.